IL-RF-IDEAS
6.3.2023 16:31:37 CET | Business Wire | Press release
rf IDEAS, a leading manufacturer of credential readers for authentication and logical access, is pleased to announce the release of the rf IDEAS FIDO2 Passwordless Platform powered by IDmelon. This end-to-end solution brings seamless, passwordless authentication to existing credentials by converting them to FIDO2 security keys – overnight.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005278/en/
FIDO2 frees organizations from password management and risk
Nearly 90% of data breaches are due to stolen passwords or human error. Passwordless single-sign on solutions are helping to combat this challenge, and migrating to more secure credentials helps arm your team with a defense mechanism.
“Partnering with rf IDEAS, and their WAVE ID® technology was a strategic decision for IDmelon – leveraging the trust and reliability of their readers to bring the FIDO2 Passwordless Platform to market allows us to jointly deliver an end-to-end solution that organizations can deploy quickly and scale affordably,” remarked CEO and co-founder of IDmelon Bahram Piri.
The rf IDEAS FIDO2 Passwordless Platform eliminates the need for centrally stored passwords that can be hacked, as well as the risk of password theft, phishing and other user-directed cyberattacks. And for users, it’s simple to roll out and easy to use. Organizations can now enable and manage passwordless authentication across credential types, devices and platforms. This rapidly growing industry standard is supported by Microsoft, Google, Apple, and all leading web services and browsers.
Ushering in a new standard for authentication
The logical access control industry is evolving rapidly to combat cyber threats and data breaches while improving the user experience of authentication without risking governance and security.
“At rf IDEAS, we have listened to our customers and are proud to release a solution that removes the complexities of credential migration, converting users quickly and securely to a higher standard of security,” said Raul Cepeda Jr., Vice President of Product and Marketing at rf IDEAS. “Now, access via security keys is possible using existing credentials, WAVE ID readers, and the rf IDEAS Passwordless Platform – evolving the way we think about migration across credentials by leveraging ID badges and smartphones to unlock potential to more secure authentication methods.”
rf IDEAS and IDmelon will be showcasing their joint solution at the upcoming Gartner IAM symposiums in London and Texas this month – to see a full listing of upcoming events visit our Events Page.
To learn more and set up a 1:1 consultation, visit rfIDEAS.com/FIDO2.
About rf IDEAS
rf IDEAS, Inc. is a leader in logical access solutions for healthcare, manufacturing, financial, government, education and enterprise. The company’s WAVE ID readers are trusted by users across the globe and backed by strong partnerships with leading identity and access management providers. rf IDEAS readers enable innovative solutions for single sign-on, secure printing, and mobile authentication while supporting nearly all credentials worldwide. For more information, visit www.rfIDEAS.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005278/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
